BRAIN Biotech AG (HAM:BNN) Institutional Ownership: 2.66% (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BNN BRAIN Biotech AG HAM:BNN
68 GF Score
Price €2.77
GF Value €2.53
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Institutional Ownership?

BRAIN Biotech AG HAM:BNN 68 Institutional Ownership is 2.66% as of Aug. 04, 2026. GuruFocus rates HAM:BNN with a GF Score™ of 68/100 and a GF Value™ of €2.53 (Fairly Valued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BRAIN Biotech AG's institutional ownership is 2.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BRAIN Biotech AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BRAIN Biotech AG's Float Percentage Of Total Shares Outstanding is 0.00%.

BRAIN Biotech AG Institutional Ownership Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Institutional Ownership Chart

BRAIN Biotech AG Historical Data

The historical data trend for BRAIN Biotech AG can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.49 4.50 4.24 4.24 2.75 2.66 2.66 2.66 2.66 2.66
HAM:BNN
68GF Score
BRAIN Biotech AG HAM:BNN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.66% mean?
BRAIN Biotech AG (HAM:BNN) has a Institutional Ownership of 2.66% as of Aug. 04, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Institutional Ownership too high?
BRAIN Biotech AG's current Institutional Ownership is 2.66%. Overall, BRAIN Biotech AG has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Institutional Ownership compare to LIN and SHW?
BRAIN Biotech AG's Institutional Ownership of 2.66% can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Chemicals company?
A good Institutional Ownership depends on the Chemicals industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Institutional Ownership is 2.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.53, compared to a current price of €2.77 — trading 9.5% above its estimated fair value. The current Institutional Ownership is 2.66%. BRAIN Biotech AG's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Institutional Ownership is 2.66% as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.77 is trading 9.5% above its estimated GF Value™ of €2.53. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for HAM:BNN:

  • Institutional Ownership: 2.66%
  • GF Value™: €2.53 vs. price of €2.77 (9.5% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
68GF Score

Get the complete analysis for HAM:BNN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.77
Price
€2.53
GF Value